Bone Medical further positive results from oral osteoporosis drug trial

Bone Medical oral drug appears to match the injectable alternative

14-May-2008

Bone Medical Limited has obtained important positive data on blood levels of peptide from testing its oral parathyroid hormone (PTH) CaPTHymone(TM) osteoporosis product. These results are from a second clinical trial of CaPTHymone(TM) conducted at Qpharm in Brisbane, Australia.

Previously, Bone announced that increases in plasma calcium were seen in subjects treated with CaPTHymone(TM) (containing 400ug or 800ug of PTH 1-34 fragment) which were equivalent to those seen hitherto for Eli Lilly's Forteo - comprising a dose of 20ug of PTH (1-34 fragment) injected sub-cutaneously. These increases in calcium demonstrated that PTH was entering the bloodstream via the oral route and exerting a biological effect.

These findings have now been backed up by further analyses, showing that increases above baseline of PTH fragments can be seen in the bloodstream shortly after administration of CaPTHymone(TM). The increases seen are comparable to those measured for injectable PTH (1-34), during Bone's first clinical trial, while placebo levels in the same trial stayed close to baseline.

CaPTHymone(TM) complements another drug in Bone's portfolio, Capsitonin(TM) (oral calcitonin), for which encouraging results in Phase IIb clinical trials have also been generated. Calcitonin targets osteoclasts, preventing them from breaking bone down, while PTH up-regulates osteoblasts, whose role is to build new bone.

Calcitonin, currently available as an injectable and nasally administered product, is indicated for early stages of osteoporosis, while injectable PTH is used in the later stages of osteoporosis, when the condition can be severe.

https://www.bionity.com/en/news/81986/bone-medical-further-positive-results-from-oral-osteoporosis-drug-trial.html